Saturday 17 October 2026
Export CRDL’s income statement to Excel — free account
Cardiol Therapeutics Inc.
CRDL Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS grew 42.9%, free cash flow grew 10.6% and total debt fell 38.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.10
0.05
−4.35%
Follow CRDL
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 1.62 | 1.08 | 1.75 | 0.47 | 0.45 | 0.82 | 0.77 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | 10.00 | 3.83 | 4.96 | 2.36 | 1.24 | 3.12 | 1.59 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 11 | 17 | 17 | 18 | 18 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | — | — | — | — | ||||
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | — | — | — | |||||
| EBT | — | (1) | (12) | (11) | (16) | (25) | (24) | (21) | (27) | (24) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | (40,197.77) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (12) | (11) | (16) | (25) | (24) | (21) | (27) | (24) | |||||
| Depreciation | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (0.06) | (0.76) | (0.41) | (0.54) | (0.58) | (0.38) | (0.33) | (0.37) | (0.28) | |||||
| Cash flow | — | (0.04) | (0.52) | (0.34) | (0.24) | (0.43) | (0.33) | (0.29) | (0.26) | (0.20) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | (0.04) | (0.52) | (0.34) | (0.24) | (0.43) | (0.34) | (0.29) | (0.26) | (0.20) | |||||
| Book value | — | 0.10 | 1.07 | 0.44 | 0.35 | 1.41 | 0.64 | 0.32 | 0.25 | 0.15 | |||||
| Shares, m | — | 23 | 15 | 26 | 30 | 43 | 63 | 64 | 72 | 87 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | — | — | — | — | ||||
| P/S | — | — | — | — | — | 0.00 | — | — | — | — | |||||
| P/B | — | — | — | — | — | 1.75 | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | 0.00 | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | (1.62) | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (1) | (8) | (9) | (7) | (19) | (21) | (19) | (18) | (17) | ||||
| Capex | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | (1) | (8) | (9) | (7) | (19) | (21) | (19) | (18) | (17) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 2 | 16 | 11 | 10 | 60 | 40 | 21 | 18 | 13 | ||||
| Total debt | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Net debt | — | (2) | (12) | (5) | (11) | (67) | (46) | (26) | (22) | (15) | |||||
| Shareholders’ equity | — | 2 | 16 | 11 | 10 | 61 | 40 | 21 | 18 | 13 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (12.82) | (128.77) | (70.00) | (133.00) | (61.10) | (40.38) | (55.64) | (106.13) | (120.54) | ||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | (14.24) | (125.25) | (76.10) | (149.55) | (70.83) | (47.12) | (68.23) | (137.37) | (156.96) | |||||
Negative figures in brackets.
Fiscal years to Dec 2021 · latest quarter Jun 2021
Charts ten years each
Cardiol Therapeutics Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics, Inc. | $192.7M | — (loss-making) | — (loss-making) | −21.36% (below 0%: shrinking) | n/m | −88.99% (below 0%: shrinking) | 78.78% | (12.88%) | Compare |
| DERM Journey Medical Corporation | $144.7M | — (loss-making) | 91.8× | +23.33% (above 0%: growing) | n/m | −84.08% (below 0%: shrinking) | 66.81% | 2.46% | Compare |
| ORGO Organogenesis | $142.8M | — (loss-making) | — (loss-making) | −56.68% (below 0%: shrinking) | n/m | +10.29% (above 0%: growing) | 45.90% | (116.54%) | Compare |
| CRDL Cardiol Therapeutics Inc. | $138.8M | — (loss-making) | — (loss-making) | — | n/m | +10.61% (above 0%: growing) | 0.00% | 0.00% | |
| OGI Organigram Global Inc. | $131.4M | 2.0× | 11.4× | +49.28% (above 0%: growing) | n/m | −192.32% (below 0%: shrinking) | 39.16% | 5.04% | Compare |
| BGM BGM Group Ltd. | $114.7M | 144× | 44.9× | −2.59% (below 0%: shrinking) | −85.71% (below 0%: shrinking) | +3.00% (above 0%: growing) | 7.12% | 0.00% | Compare |
| PROCF Sofgen Pharma S.A | $114.0M | 0.1× | 4.0× | +17.28% (above 0%: growing) | n/m | +231.11% (above 0%: growing) | 56.09% | 36.48% | Compare |
| CPIX Cumberland Pharmaceuticals Inc. | $113.0M | — (loss-making) | — (loss-making) | −56.28% (below 0%: shrinking) | n/m | −82.78% (below 0%: shrinking) | 100.00% | (1,898.20%) | Compare |
| CLVR Clever Leaves Holdings Inc. | $96.5M | — (loss-making) | — (loss-making) | +5.36% (above 0%: growing) | n/m | +70.31% (above 0%: growing) | (7.46%) | (105.91%) | Compare |
| Median of peers | $123.0M | 2.0× | 28.2× | +1.39% | — | −39.89% | 51.00% | (6.44%) |
Cardiol Therapeutics Inc. (CRDL) key facts
- Cardiol Therapeutics Inc. (CRDL) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CRDL traded at $1.10, a market capitalization of $138.8 million.
- Return on equity was −157.0% and debt-to-equity 0.00.
Cardiol Therapeutics Inc. (CRDL) Latest News
No news at this impact. Lower the threshold for more.